OPEN STUDIES
OVARIAN
BGOG-ov-50
Pivotal, randomized, open-label study of Tumor Treating Fields (TTFields, 200kHz) concomitant with weekly paclitaxel for the treatment of platinum-resistant ovarian cancer (PROC)
Sponsor: Novocure
Participating sites:
- CHU UCL Namur, site Sainte Elisabeth, Namur
- UZ Gent, Gent
- UZ Leuven, Leuven
- CHU Ambroise Paré, Mons
- AZ Maria Middelares, Gent
- CHU Dinant Godinne, Yvoir
- Grand Hôpital de Charleroi, Charleroi
- Imelda ziekenhuis, Bonheiden
- CHU UCL St-Luc, Bruxelles
Learn More ->
BGOG-ov-46
Phase III Randomised, Double Blind, Placebo Controlled, Multicentre Study of durvalumab in combination with chemotherapy and bevacizumab followed by maintenance durvalumab, bevacizumab and olaparib in newly diagnosed advanced ovarian cancer patients
Sponsor: AstraZeneca
Participating sites:
- AZ Nikolaas, St-Niklaas
- AZ Damiaan, Oostende
- OLV Aalst, Aalst
- UZ Leuven, Leuven
- CHU UCL Namur, site Sainte Elisabeth, Namur
Learn More ->
BGOG-ov-44
A Randomized, Double-Blind, Phase 3 Comparison of Platinum-Based Therapy with TSR-042 and Niraparib Versus Standard of Care Platinum-Based Therapy as First-line Treatment of Stage III or IV Nonmucinous Epithelial Ovarian Cancer
Sponsor: GSK/Tesaro
Participating sites:
- UZ Leuven, Leuven
- AZ Sint-Jan Brugge, Brugge
- CHU St. Pierre, Bruxelles
- AZ Klina, Brasschaat
Learn More ->
BGOG-ov-43
A Randomized Phase 3, Double-Blind Study of Chemotherapy With or Without Pembrolizumab Followed by Maintenance With Olaparib or Placebo for the FirstLine Treatment of BRCA non-mutated Advanced Epithelial Ovarian Cancer (EOC)
Sponsor: Merck Sharp & Dohme Corp.
Participating sites:
- AZ Maria Middelares, Gent
- Imelda Ziekenhuis, Bonheiden
- Grand Hôpital de Charleroi, Charleroi
- Hôpital de Libramont, Libramont
- UZ Leuven, Leuven
- UZ Gent, Gent
- Jessa Ziekenhuis, Hasselt
- CHU de Liège, site Sart Tilman, Liège
- UZ Antwerpen, Antwerpen
- CHU UCL St-Luc, Bruxelles
Learn More ->
BGOG-ov-41
A phase III randomized, double-blinded trial of platinum-based chemotherapy with or without atezolizumab followed by niraparib maintenance with or without atezolizumab in patients with recurrent ovarian, tubal or peritoneal cancer and platinum treatment-free interval (TFIp) >6 months
Sponsor: Grupo Español de Investigación en Cáncer de Ovario (GEICO)
Participating sites:
- UZ Leuven, Leuven
- CHU Ambroise Paré, Mons
- CHU UCL Namur, site Sainte Elisabeth, Namur
- CHU UCL St. Luc, Bruxelles
- Grand Hôpital de Charleroi, Charleroi
- CHU de Liège, site Sart Tilman, Liège
Learn More ->
BGOG-ov-55
MIRASOL: A Randomized, Open-label, Phase 3 Study of Mirvetuximab Soravtansine vs. Investigator’s Choice of Chemotherapy in Advanced High Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers with High Folate Receptor-Alpha Expression
Sponsor: ImmunoGen
Participating sites:
- Hôpital de Libramont, Libramont
- UZ Leuven, Leuven
- OLV Aalst, Aalst
- UZ Antwerpen, Antwerpen
- AZ Sint Lucas, Gent
- AZ Klina, Roeselare
Learn More ->
ENDOMETRIUM
BGOG-en-6
A Phase 3, Randomized, Double-blind, Multicenter Study Comparing TSR-042 plus Paclitaxel and Carboplatin versus Paclitaxel and Carboplatin plus Placebo in Patients with Recurrent or Advanced Endometrial Cancer Who Had Received no Previous Systemic Anticancer therapy for Advanced or Metastatic Disease
Sponsor: GSK/Tesaro
Participating sites:
- UZ Leuven, Leuven
- CHU de Liège, site Sart Tilman, Liège
- OLV Aalst, Aalst
Learn More ->
BGOG-en-9
A Phase 3 Randomized, Open-Label, Study of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Versus Chemotherapy for First-line Treatment of Advanced or Recurrent Endometrial Carcinoma (LEAP-001)
Sponsor: Merck Sharp & Dohme Corp.
Participating sites:
- UZ Leuven, Leuven
- CHU UCL St-Luc, Bruxelles
- UZ Antwerpen, Antwerpen
- AZ Maria Middelares, Gent
- AZ Delta, Roeselare
Learn More ->
BGOG-en-10
Randomized, Multi-Center, Double Blind Phase III Study of First-line Carboplatin and Paclitaxel in Combination with Durvalumab, Followed by Maintenance Durvalumab with or without Olaparib in Patients with Newly Diagnosed Advanced or Recurrent Endometrial Cancer
Sponsor: AstraZeneca
Participating sites:
- UZ Leuven, Leuven
- UZ Gent, Gent
- CHU UCL St-Luc, Bruxelles
- Hôpital de Libramont, Libramont
- AZ Groeninge, Kortrijk
- AZ Sint Jan Brugge, Brugge
- Grand Hôpital de Charleroi, Charleroi
- Clinique CHC Montlégia, Liège
- Jessa Ziekenhuis, Hasselt
Learn More ->
VULVAR
CERVIX
BGOG-cx-8
A Phase 1b/2 Open-Label Trial of Tisotumab Vedotin (HuMax® ®-TF -ADC) in Combination with Other Agents in Subjects with Recurrent or Stage IVB Cervical Cancer
Sponsor: Genmab
Participating sites:
- UZ Leuven, Leuven
- CHU de Liège, site Sart Tilman, Liège
- UZ Antwerpen, Antwerpen
- CHU UCL St-Luc, Bruxelles
- Grand Hôpital de Charleroi, Charleroi
- CHU UCL St-Luc, Bruxelles
- AZ Sint-Jan Brugge, Brugge
- UZ Gent, Gent
- Hôpital de Libramont, Libramont
Learn More ->
BGOG-cx-11
A randomized, Phase 3, double-blind study of radiochemotherapy with or without Pembrolizumab for the treatment of high-risk, locally advanced cervical cancer
Sponsor: Merck Sharp & Dohme Corp.
Participating sites:
- AZ Sint-Lucas, Gent
- UZ Leuven, Leuven
- GZA campus Sint-Augustinus, Antwerpen
- OLV Aalst, Aalst
- CHU Ambroise Paré, Mons
- UZA, Antwerpen
Learn More ->
UPCOMING STUDIES
BGOG-ov-34
Atezolizumab in combination with Bevacizumab and Chemotherapy versus Chemo-Bevacizumab in recurrent ovarian cancer – a randomized Phase III trial
Sponsor: AGO Study Group
Learn More ->
BGOG-cx-12
A Randomized, Open-Label, Phase 3 Trial of Tisotumab Vedotin vs Investigator’s Choice Chemotherapy in Secondor Third-Line Recurrent or Metastatic Cervical Cancer
Sponsor: Genmab
Learn More ->
BGOG-en-11
A Phase 3, Randomized, Double‐Blind Study of Pembrolizumab versus Placebo in Combination With
Adjuvant Chemotherapy With or Without Radiotherapy for the Treatment of Newly Diagnosed High‐Risk Endometrial Cancer After Surgery With Curative Intent
Sponsor: Merck Sharp & Dohme Corp.
Learn More ->
BGOG-en-12
An Umbrella Study of INCMGA00012 Alone and in Combination With Other Therapies in Participants With Advanced or Metastatic Endometrial Cancer Who Have Progressed on or After Platinum-Based Chemotherapy (POD1UM-204)
Sponsor: Incyte
Participating sites:
- Institut Jules Bordet, Bruxelles
- CHU de Liège, site Sart Tilman, Liège
- UZ Gent, Gent
- UZ Leuven, Leuven
Learn More ->
CLOSED FOR ACCRUAL
BGOG-cx-9
An Open-Label, Randomized, Phase 3 Clinical Trial of the checkpoint inhibitor REGN2810 versus Therapy of Investigator’s Choice Chemotherapy in Recurrent or metastatic Platinum-Refractory Cervical Carcinoma
Sponsor: Regeneron Pharmaceuticals, Inc
Participating sites:
- CHU UCL Namur, site Sainte Elisabeth, Namur
- UZ Leuven, Leuven
- Clinique CHC Montlégia, Liège
- Institut Jules Bordet, Bruxelles
- CHU UCL St. Luc, Bruxelles
- OLV Aalst, Aalst
- CHU de Liège, site Sart Tilman, Liège
Learn More ->
BGOG-ov-1
A Phase II international multicenter randomized study testing the effect on survival of prolonging platinum-free interval in patients with ovarian cancer recurring between 6 and 12 months after previous platinum based chemotherapy.
Learn More ->
BGOG-en-1
A randomized phase II trial of first-line combination chemotherapy with nintedanib / placebo for patients with advanced or recurrent endometrial cancer.
Learn More ->
BGOG-cx-1
Randomized double-blind Phase II study comparing 3-weekly carboplatin (AUC 5 or 6) + paclitaxel 175 mg/m2 with or without concomitant and maintenance Nintedanib in advanced or recurrent cervical carcinoma.
Learn More ->
BGOG-ov-2
A Phase III Study to Evaluate the Efficacy and Safety of Pazopanib Monotherapy Versus Placebo in Women Who Have not Progressed after First Line Chemotherapy for Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer.
Learn More ->
BGOG-en-2
A phase III Trial of postoperative chemotherapy or no further treatment for patients with node-negative stage I-II intermediate or high risk endometrial cancer.
Learn More ->
BGOG-cx-2
A Randomized Phase III Trial comparing radical hysterectomy and pelvic node dissection vs simple hysterectomy and pelvic node dissection in patients with low-risk early-stage cervical cancer.
Learn More ->
BGOG-ov-3
A Multicentre, Randomized, Double-Blind, Phase III Trial to Investigate the Efficacy and Safety of BIBF 1120 in Combination with Standard Treatment of Carboplatin and Paclitaxel Compared to Placebo plus Carboplatin and Paclitaxel in Patients with Advanced Ovarian Cancer.
Learn More ->
BGOG-ov-4
Phase III Randomised Study of Bevacizumab plus Chemotherapy versus Chemotherapy alone in Patients with Platinum Resistant Ovariumcancer.
Learn More ->
BGOG-ov-5
Phase II study of weekly paclitaxel/carboplatin in combination with prophylactic G-CSF in the treatment of gynaecological cancers.
Learn More ->
BGOG-cx-6
A Single arm, Multicenter, International Trial of Tisotumab Vedotin (HuMax®-TF-ADC) in Previously Treated, Recurrent or Metastatic Cervical Cancer.
Learn More ->
BGOG-ov-6
A Phase 3, Randomized, Double-Blind Trial of Pegylated Liposomal Doxorubicin (PLD) Plus AMG 386 or Placebo in Women With Recurrent Partially Platinum Sensitive or Resistant Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer.
Learn More ->
BGOG-ov-7
Randomized Phase III trial of Paclitaxel-Carboplatin with or without concomittant and maintenance AMG386 as First-line therapy of Stage III-IV ovarian, fallopian tube and peritoneal carcinoma.
Learn More ->
BGOG-ov-8
Phase III, multicenter, randomized study of Trabectedin plus Pegylated Liposomal Doxorubicin (PLD) versus Carboplatin plus PLD in patients with ovarian cancer progressing within 6-12 months of last platinum.
Learn More ->
BGOG-ov-9
A Randomized multicenter study to compare the efficacy of additional tumor debulking surgery versus chemotherapy alone for recurrent platinum-sensitive ovarian cancer.
Learn More ->
BGOG-ov-11
The MILO Study (MEK Inhibitor in Low-grade Serous Ovarian Cancer):A Multinational, Randomized, Open-label Phase 3 Study of MEK162 vs. Physician’s Choice Chemotherapy in Patients with Recurrent or Persistent Low-grade Serous Carcinomas of the Ovary, Fallopian Tube or Primary Peritoneum.
Learn More ->
BGOG-ov-13
A randomized, open label, phase II trial of bevacizumab plus weekly paclitaxel followed by bevacizumab monotherapy maintenance versus weekly paclitaxel followed by observation in patients with relapsed ovarian sex-cord stromal tumours.
Learn More ->
BGOG-ov-14
A Phase 3 Randomized Double-blind Trial of Maintenance with Niraparib versus Placebo in Patients with Platinum Sensitive Ovarian Cancer.
Learn More ->
BGOG-ov-15
A Phase III Randomised, Double Blind, Placebo Controlled, Multicentre Study of Olaparib Maintenance Monotherapy in Platinum Sensitive Relapsed BRCA Mutated Ovarian Cancer Patients who are in Complete or Partial Response Following Platinum based Chemotherapy
Learn More ->
BGOG-ov-16
A non-interventional Belgian study to collect data on the safety and efficacy of frontline Bevacizumab treatment in ovarian cancer patients ≥70 years.
Learn More ->
BGOG-ov-17
A multicenter Phase III randomized study with second line chemotherapy plus or minus Bevacizumab in patients with Platinum sensitive Epithelial ovarian cancer recurrence after a Bevacizumab/Chemotherapy first line.
Learn More ->
BGOG-ov-18
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Assess the Efficacy and Safety of Farletuzumab (MORAb-003) in Combination with Carboplatin plus Paclitaxel or Carboplatin plus Pegylated Liposomal Doxorubicin (PLD) in Subjects with Low CA125 Platinum-Sensitive Ovarian Cancer.
Learn More ->
BGOG-ov-19
Randomized, Double-Blind, Phase III Trial of Olaparib vs. Placebo in Patients with Advanced FIGO Stage IIIB – IV High Grade Serous or Endometrioid Ovarian, Fallopian Tube, or Peritoneal Cancer treated with standard First-Line Treatment, Combining Platinum-Taxane Chemotherapy and Bevacizumab Concurrent with Chemotherapy and in Maintenance.
Learn More ->
BGOG-ov-26
Phase 3 Maintenance Study to Evaluate the Efficacy and Safety of Niraparib Versus Placebo in women who have not progressed after first line chemotherapy for Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Learn More ->